Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
2.
Urogynecology (Phila) ; 28(8): 554-560, 2022 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-35649241

RESUMEN

IMPORTANCE: There are limited studies evaluating the effect of preoperative interventions on postoperative bowel function after prolapse surgery. OBJECTIVE: The objective of this study was to evaluate if preoperative fiber intake reduces time to first bowel movement after surgery for pelvic organ prolapse. STUDY DESIGN: We performed a randomized controlled trial of women undergoing pelvic organ prolapse surgery between July 2019 and May 2021. Participants were recruited at their preoperative visit and randomized to receive either 3.4 g psyllium fiber supplementation twice a day for 1 week before surgery or no fiber supplementation before surgery. Postoperative bowel regimen was standardized for both groups. Participants completed a bowel diary for their first postoperative bowel movement after surgery characterized by the Bristol Stool Scale and any associated pain or urgency. The primary outcome was time to first bowel movement. Secondary outcomes included pain associated with first bowel movement. RESULTS: Eighty-four patients were enrolled in the study. Seventy-one patients had complete data for primary analysis, with 35 patients in the intervention group and 36 patients in the control group. Demographic and perioperative characteristics were similar between the groups. There was no difference found between the groups with respect to time to first bowel movement (control: 68.3 [SD, 25] hours vs intervention: 66.5 [SD, 23] hours, P = 0.749). There was no difference found with pain associated with first bowel movement (visual analog scale median [interquartile range] control: 2.0 [0.0-4.0] vs intervention: 2.0 [1.0-4.0]; P = 0.655). CONCLUSIONS: Preoperative fiber supplementation before prolapse surgery does not improve time to first bowel movement after surgery.


Asunto(s)
Prolapso de Órgano Pélvico , Procedimientos de Cirugía Plástica , Psyllium , Humanos , Femenino , Defecación , Prolapso de Órgano Pélvico/cirugía , Fibras de la Dieta , Dolor/cirugía
3.
Female Pelvic Med Reconstr Surg ; 27(2): 85-89, 2021 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-31033527

RESUMEN

OBJECTIVES: The objective of our study was to determine if phenazopyridine reduces void trial (VT) failure rates after prolapse surgery. METHODS: A single-institution randomized controlled trial was conducted comparing a second dose of phenazopyridine 200 mg on postoperative day 1 versus no additional phenazopyridine in women undergoing prolapse surgery. All subjects (including controls) received 200 mg of phenazopyridine preoperatively for ureteral patency verification. The intervention group received a second dose of phenazopyridine 200 mg the morning of postoperative day 1. The primary outcome was assessed using a standardized VT. Secondary outcomes included pain, opioid usage, urinary tract infections, and prolonged or recurrent urinary retention. An intent-to-treat analysis was performed with a χ2 test to compare failure rates between the intervention and control groups. RESULTS: We enrolled 152 women, and 76 were randomized to each group. There was no difference in VT failures between the 2 groups-34% failed without phenazopyridine on postoperative day 1, and 42% failed with phenazopyridine on postoperative day 1 (P = 0.326). Subject characteristics were similar across both groups. Pain scores immediately before the VT were 3 out of 10 in both groups (P = 0.206), with no difference in opioid consumption (P = 0.750). There were no differences in the rate of urinary tract infections or prolonged or recurrent urinary retention between the groups (P = 0.304 and P = 0.745). CONCLUSIONS: While previous studies suggested an improvement in immediate postoperative voiding with phenazopyridine, our randomized controlled trial does not support this.


Asunto(s)
Anestésicos/administración & dosificación , Prolapso de Órgano Pélvico/cirugía , Fenazopiridina/administración & dosificación , Complicaciones Posoperatorias/prevención & control , Retención Urinaria/prevención & control , Femenino , Humanos , Persona de Mediana Edad , Cuidados Posoperatorios , Premedicación
4.
Female Pelvic Med Reconstr Surg ; 24(2): 95-99, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29474280

RESUMEN

OBJECTIVE: To determine the effect of preoperative oral phenazopyridine on postoperative voiding dysfunction in women undergoing a retropubic midurethral sling. METHODS: A single-institution randomized clinical trial was performed from September 2015 to March 2017, comparing 200 mg of oral phenazopyridine versus no phenazopyridine in patients undergoing a retropubic midurethral sling under general anesthesia with no concomitant procedures. A power calculation indicated that we required at least 40 subjects per arm. Preoperative demographics, intraoperative medications, blood loss, and complications were recorded. A standardized voiding trial was performed before discharge. Voiding dysfunction was determined by the proportion of subjects who failed a postoperative voiding trial. Pain scores were obtained before and 2 to 3 hours after the surgical procedure. Patient characteristics and surgical data were compared using χ, Fisher exact test, or Wilcoxon rank sum test. RESULTS: Ninety-two subjects were enrolled in the study. Three patients cancelled their surgery and 1 had an intraoperative urethral injury, leaving 88 patients for the final analysis (44 per arm). Patient demographics showed no differences between groups. Phenazopyridine did not reduce the proportion of patients who failed the voiding trial (27%) compared with subjects who did not receive the medication (21%) (P = 0.453). Postoperative visual analog pain scores were higher in those not receiving phenazopyridine (1.76 vs 1.21, P = 0.046), but after adjusting for the difference in preoperative and postoperative pain scores, the groups showed no difference (P = 0.087). CONCLUSIONS: Our prospective trial shows that phenazopyridine has no effect on short-term postoperative voiding dysfunction. This condition appears to be multifactorial, and further research is needed.


Asunto(s)
Anestésicos Locales/administración & dosificación , Fenazopiridina/administración & dosificación , Complicaciones Posoperatorias/prevención & control , Cabestrillo Suburetral , Retención Urinaria/prevención & control , Administración Oral , Anestesia General , Índice de Masa Corporal , Femenino , Humanos , Persona de Mediana Edad , Cuidados Preoperatorios , Estudios Prospectivos , Resultado del Tratamiento , Incontinencia Urinaria de Esfuerzo/cirugía , Retención Urinaria/etiología
5.
Female Pelvic Med Reconstr Surg ; 24(1): 43-47, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-28230566

RESUMEN

OBJECTIVE: The aim of this study was to determine the effect of preoperative oral phenazopyridine on short-term voiding dysfunction in patients undergoing a retropubic midurethral sling. METHODS: We conducted a retrospective cohort study in subjects undergoing a retropubic midurethral sling comparing those who received preoperative oral phenazopyridine with those who did not. We included all women who underwent a retropubic midurethral sling without concomitant procedures under general anesthesia at our institution. Slings were placed by either suprapubic or transvaginal approach, per surgeon's preference. Demographics and intraoperative data on preoperative dose of phenazopyridine and medications linked to voiding dysfunction were captured. RESULTS: One hundred seventy-four subjects were identified. Twenty-five subjects failed to meet inclusion and exclusion criteria and were excluded, and 149 subjects comprised the final groups. Eighty-two subjects (55.03%) received phenazopyridine, and 67 (44.97%) did not. Most subjects received a 200-mg dose (97.6%). Except for surgical approach, both groups receiving and not receiving phenazopyridine had similar demographic characteristics. Eighty-eight percent of the subjects who received phenazopyridine passed the voiding trial versus 73.1% (odds ratio, 2.98; 95% confidence interval, 1.23-7.17). After adjusting for medications, estimated blood loss, number of trocar passages, or bladder perforation, the patients receiving phenazopyridine were still more likely to pass the postoperative voiding trials compared with those who did not (odds ratio, 2.97; 95% confidence interval, 1.10-7.98). CONCLUSIONS: Our findings suggest that the preoperative administration of phenazopyridine may improve postoperative voiding function after a retropubic midurethral sling. Additional prospective trials are needed to confirm this finding.


Asunto(s)
Anestésicos Locales/administración & dosificación , Fenazopiridina/administración & dosificación , Complicaciones Posoperatorias/prevención & control , Cabestrillo Suburetral , Retención Urinaria/prevención & control , Adulto , Estudios de Casos y Controles , Femenino , Procedimientos Quirúrgicos Ginecológicos/métodos , Humanos , Modelos Logísticos , Persona de Mediana Edad , Cuidados Preoperatorios , Estudios Retrospectivos , Incontinencia Urinaria de Esfuerzo/cirugía
7.
Female Pelvic Med Reconstr Surg ; 22(4): 287-9, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27171323

RESUMEN

BACKGROUND: Midurethral slings are an effective treatment method for stress urinary incontinence (SUI). Although success rates can be as high as 90%, the remaining patients with disappointing results may require further surgical intervention. In particular, those patients with persistent SUI may need further revision of the existing sling. Literature is limited in the optimal treatment of these patients. CASE SERIES: Five patients who underwent midurethral slings for SUI and had subsequent sling revision were included in this analysis. The technique of revision is outlined in this article. Subsequently, these patients had greatly improved continence. CONCLUSIONS: Our patients did benefit from this method of sling revision. Further information on sling revisions with increased patient populations would allow us to make appropriate recommendations.


Asunto(s)
Reoperación/métodos , Cabestrillo Suburetral/efectos adversos , Incontinencia Urinaria de Esfuerzo/cirugía , Femenino , Humanos , Resultado del Tratamiento
8.
Artículo en Inglés | MEDLINE | ID: mdl-26825411

RESUMEN

OBJECTIVES: The purpose of this systematic review was to evaluate and summarize pharmacological interventions evaluated in randomized clinical trials designed to prevent recurrent episodes of urinary tract infections (UTIs) in postmenopausal women. METHODS: Excerpta Medica dataBASE, Pubmed, Medline, and Cochrane Library were accessed to search for nonexperimental drugs evaluated in randomized clinical trials published in peer reviewed journals from January 1, 1970, to August 1, 2015, to reduce the number of recurrent UTIs in postmenopausal women. RESULTS: A systematic search yielded 9 articles that met eligibility criteria. Five articles involved the use of systemic or vaginal estrogen therapy and the remainder used oral antibiotics, lactobacilli, or a combination of interventions. Antibiotics were the most efficacious therapy but with a higher incidence of systemic side effects. Oral lactobacillus was noninferior to sulfamethoxazole with trimethoprim with a safer profile in 1 small study. Vaginal estrogen appeared to be inferior to continuous oral antibiotic suppression; however, use of multiple formulations of both treatment options precludes meta-analysis. Oral estrogen use did not decrease UTI recurrence and resulted in local and systemic side effects in up to nearly 30% of the patients. CONCLUSIONS: This review supports the use of antibiotic suppression, vaginal estrogen, and oral lactobacillus for prevention of recurrent UTIs in postmenopausal women. However, the overall dearth of data suggests that this is an important but understudied population. Because the effectiveness and safety of available treatments are not well understood, they should be used with caution in older populations, pending further study.


Asunto(s)
Antibacterianos/uso terapéutico , Estrógenos/uso terapéutico , Posmenopausia , Infecciones Urinarias/prevención & control , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Lactobacillus , Persona de Mediana Edad , Ensayos Clínicos Controlados Aleatorios como Asunto , Prevención Secundaria , Resultado del Tratamiento
9.
Obstet Gynecol Surv ; 63(4): 253-66, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18348739

RESUMEN

UNLABELLED: Urinary incontinence and pelvic organ prolapse are some of the most commonly treated conditions in postmenopausal women. Surgical cure rates vary greatly depending on surgical technique and the type of materials used, if any, to supplement the native tissue. Traditional colporrhaphy relies on adequate tissue for a successful repair. The main concern associated with traditional plication or needle suspension type repairs is that the use of intrinsic attenuated tissue may provide a weak, constricted, or an anatomically incorrect result. Graft use allows for a broader base of support and eliminates the need to rely on the existing weakened fascia and musculature. A review of the existing literature on success rates and complications with various synthetic and biologic graft materials yielded the following conclusions. The superiority of graft use over traditional suture suspensions for abdominal sacrocolpopexy and suburethral sling procedures has clearly been shown in the literature. Macroporous monofilament synthetic grafts and non-cross-linked biologic grafts appear to have the best integration into native tissues. Solvent dehydration and irradiation of biologic grafts may weaken the integrity of the material and may prevent proper tissue integration. Technical factors related to surgical technique may impact success rates, such as tension on suture line or failure to use vaginal packing. The perfect graft material has not yet been created. Suggestions for further research include more prospective, randomized trials comparing synthetic and biologic grafts, tension-free versus secured mesh, and absorbable versus nonabsorbable mesh. TARGET AUDIENCE: Obstetricians & Gynecologists, Family Physicians Learning Objectives: After completion of this article, the reader should be able to recall how common urinary incontinence is, explain the historical considerations for diagnosis and treatment, and summarize the updated methods of treatment based upon anatomical structures and pathophysiology.


Asunto(s)
Prolapso Rectal/cirugía , Trasplantes , Incontinencia Urinaria/cirugía , Prolapso Uterino/cirugía , Materiales Biocompatibles , Femenino , Procedimientos Quirúrgicos Ginecológicos/métodos , Humanos , Posmenopausia , Cuidados Posoperatorios , Cabestrillo Suburetral , Mallas Quirúrgicas , Técnicas de Sutura
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA